Cosmo NV (LTS:0RGI) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RGI Cosmo NV LTS:0RGI
76 GF Score
Price CHF63.20
GF Value CHF43.15
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cosmo NV FFO per Share?

FFO per Share only applies to REITs.

LTS:0RGI
76GF Score
Cosmo NV LTS:0RGI
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cosmo NV (LTS:0RGI) Overvalued in 2026?

Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued. The current stock price of CHF63.20 is trading 46.5% above its estimated GF Value™ of CHF43.15. GuruFocus considers Cosmo NV to be Significantly Overvalued.

Key valuation signals for LTS:0RGI:

  • FFO per Share:
  • GF Value™: CHF43.15 vs. price of CHF63.20 (46.5% above fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RGI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cosmo NV Business Description

Address 91/94 North Wall Quay, 7th Floor, One North Dock, Dublin, IRL, D01 H7V7
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
76GF Score

Get the complete analysis for LTS:0RGI

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF63.20
Price
CHF43.15
GF Value